Valuation: Alector, Inc.

Market Cap 292M 260M 241M 218M 410M 27.59B 416M 2.88B 1.13B 14.49B 1.1B 1.07B 46.18B P/E 2026 *
-4.36x
P/E 2027 * -2.35x
Enterprise Value 30.06M 26.77M 24.78M 22.45M 42.23M 2.84B 42.8M 297M 116M 1.49B 113M 110M 4.75B EV / Sales 2026 *
0.45x
EV / Sales 2027 * -1.21x
Free-Float
92.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-5.08%
Current month+1.08%
1 month-2.09%
3 months+30.77%
6 months-30.87%
Current year+19.87%
1 week 1.76
Extreme 1.765
2.18
1 month 1.73
Extreme 1.73
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
2.76
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 30/04/2013
Director of Finance/CFO 52 19/06/2025
Chief Tech/Sci/R&D Officer - 31/12/2016
Director TitleAgeSince
Director/Board Member 71 30/04/2013
Director/Board Member 72 30/09/2018
Chairman 77 12/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Free

Controller/Auditor

138,990 0.1245%
14/10/26 Free

Founder

1,196,250 1.0714%
14/10/26 Free

Chief Financial Officer

234,567 0.2101%
Change 5-day change 1-year change 3-year change Capi.($)
-5.08%0.00%-43.50%-64.65% 292M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average -0.26%+4.83%+42.39%+104.23% 38.78B
Weighted average by Cap. +0.31%+4.67%+51.21%+127.63%

Financials

2026 *2027 *
Net sales 66.15M 58.9M 54.53M 49.4M 92.92M 6.25B 94.18M 653M 256M 3.28B 248M 243M 10.46B 11.4M 10.15M 9.39M 8.51M 16.01M 1.08B 16.23M 113M 44.15M 565M 42.75M 41.86M 1.8B
Net income -51.03M -45.44M -42.07M -38.11M -71.69M -4.82B -72.66M -504M -198M -2.53B -191M -187M -8.07B -111M -98.68M -91.35M -82.76M -156M -10.47B -158M -1.09B -429M -5.5B -416M -407M -17.52B
Net Debt -262M -233M -216M -196M -368M -24.75B -373M -2.59B -1.02B -13B -983M -962M -41.43B -306M -272M -252M -228M -430M -28.89B -435M -3.02B -1.18B -15.17B -1.15B -1.12B -48.36B
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
21/10/26 US$1.870 -5.08% 1,107,315
20/10/26 US$1.970 +1.03% 2,021,359
19/10/26 US$1.950 +5.98% 2,367,825
16/10/26 US$1.840 -3.66% 5,157,884
15/10/26 US$1.910 +1.60% 1,630,377
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.970USD
Average target price
3.900USD
Spread / Average Target
+97.97%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock